SKNV Announces Exclusive Commercialization Rights to Washington University Patent Portfolio Covering Combination of Fluorouracil and Calcipotriene Therapies
Patented combination technology aligns with recent American Academy of Dermatology guidelines on the benefits of field-directed therapy for Actinic Keratosis which include the potential to reduce the risk of squamous cell carcinoma FORT LAUDERDALE, Fla., July 22, 2026 /PRNewswire/ --...
Patented combination technology aligns with recent American Academy of Dermatology guidelines on the benefits of field-directed therapy for Actinic Keratosis which include the potential to reduce the risk of squamous cell carcinoma FORT LAUDERDALE, Fla., July 22, 2026 /PRNewswire/ --...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.